VIVOZON Pharmaceutical, The Republic of Korea - Komachine Supplier Profile and Product List

- Vivozon Pharmaceutical is a pharmaceutical company specializing in the development of professional and general medicines, tracing its origins to Gyeongseong Pharmaceutical in 1938. The company focuses on innovative new drug research and development, particularly in non-narcotic analgesics and central nervous system (CNS) disease treatments. Although it previously engaged in the manufacturing and sale of LED products for IT display BLUs and automotive lighting, its current core business and growth driver is the pharmaceutical sector. The company aims to contribute to human health improvement through new formulation technologies and innovative quality improvement techniques.Vivozon Pharmaceutical is a pharmaceutical company specializing in the development of professional and general medicines, tracing its origins to Gyeongseong Pharmaceutical in 1938. The company focuses on innovative new drug research and development, particularly in non-narcotic analgesics and central nervous system (CNS) disease treatments. Although it previously engaged in the manufacturing and sale of LED products for IT display BLUs and automotive lighting, its current core business and growth driver is the pharmaceutical sector. The company aims to contribute to human health improvement through new formulation technologies and innovative quality improvement techniques.
- Key product lines include 'Unafra injection' (Opiranserin, VVZ-149), the 38th Korean new drug, a non-narcotic analgesic administered as an injection for the short-term management of moderate to severe acute pain after surgery. Unafra injection demonstrates analgesic efficacy comparable to narcotic analgesics but without the risks of addiction and misuse, representing an innovative new drug. This product is characterized by a multi-mechanism action that simultaneously inhibits Glycine Transporter Type 2 (GlyT2) and Serotonin Receptor 2a (5HT2a).Key product lines include 'Unafra injection' (Opiranserin, VVZ-149), the 38th Korean new drug, a non-narcotic analgesic administered as an injection for the short-term management of moderate to severe acute pain after surgery. Unafra injection demonstrates analgesic efficacy comparable to narcotic analgesics but without the risks of addiction and misuse, representing an innovative new drug. This product is characterized by a multi-mechanism action that simultaneously inhibits Glycine Transporter Type 2 (GlyT2) and Serotonin Receptor 2a (5HT2a).
- The pipeline includes 'VVZ-2471', an oral non-narcotic analgesic candidate, an antagonist with potential for opioid addiction treatment and neuropathic pain relief. Additionally, the company has a robust pipeline in CNS diseases, including 'VVZ-3416' for Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders, and 'N3' as a schizophrenia treatment candidate.The pipeline includes 'VVZ-2471', an oral non-narcotic analgesic candidate, an antagonist with potential for opioid addiction treatment and neuropathic pain relief. Additionally, the company has a robust pipeline in CNS diseases, including 'VVZ-3416' for Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders, and 'N3' as a schizophrenia treatment candidate.
- The core technology held by the company is a 'multi-target drug discovery platform' capable of developing drugs that act simultaneously on multiple disease-causing factors. This platform's effectiveness has been proven through the successful development of Opiranserin. Furthermore, new formulation development technologies and innovative quality improvement techniques contribute to product differentiation and competitive advantage.The core technology held by the company is a 'multi-target drug discovery platform' capable of developing drugs that act simultaneously on multiple disease-causing factors. This platform's effectiveness has been proven through the successful development of Opiranserin. Furthermore, new formulation development technologies and innovative quality improvement techniques contribute to product differentiation and competitive advantage.
- Past business areas included the manufacturing and sale of LED PKG and MODULE for IT Display BLU, general, and automotive lighting. Product categories such as 'Lighting Part', 'Automotive', 'Display BLU', and 'LED Linear Lamp (External SMPS)', along with models like 'LMMTP721AWHZ120-C00' and 'LUMIMICRO Series', were part of its historical product portfolio.Past business areas included the manufacturing and sale of LED PKG and MODULE for IT Display BLU, general, and automotive lighting. Product categories such as 'Lighting Part', 'Automotive', 'Display BLU', and 'LED Linear Lamp (External SMPS)', along with models like 'LMMTP721AWHZ120-C00' and 'LUMIMICRO Series', were part of its historical product portfolio.
- The non-narcotic analgesic 'Unafra injection' offers powerful pain control comparable to opioid analgesics while being free from addiction and adverse effect risks, establishing a significant competitive advantage as an effective alternative to the opioid misuse crisis.The non-narcotic analgesic 'Unafra injection' offers powerful pain control comparable to opioid analgesics while being free from addiction and adverse effect risks, establishing a significant competitive advantage as an effective alternative to the opioid misuse crisis.
- The multi-target drug discovery platform technology enables the development of drugs that act on multiple disease-causing factors simultaneously, overcoming the limitations of conventional single-target drugs and expanding therapeutic possibilities for various diseases.The multi-target drug discovery platform technology enables the development of drugs that act on multiple disease-causing factors simultaneously, overcoming the limitations of conventional single-target drugs and expanding therapeutic possibilities for various diseases.
- Proactive global patent portfolio construction strategies and achievements such as US FDA Fast Track designation and IND approval serve as crucial foundations for global technology transfer and commercialization strategies.Proactive global patent portfolio construction strategies and achievements such as US FDA Fast Track designation and IND approval serve as crucial foundations for global technology transfer and commercialization strategies.
- An advanced manufacturing system adhering to KGMP regulations and stringent quality control, ensuring perfection from raw material intake to product shipment, guarantees the reliability and safety of its pharmaceutical products.An advanced manufacturing system adhering to KGMP regulations and stringent quality control, ensuring perfection from raw material intake to product shipment, guarantees the reliability and safety of its pharmaceutical products.
- Expanding the supply of 'Unafra injection' to major general and university hospitals in Korea, particularly the successful passage of Pharmacy and Therapeutics Committee (DC) reviews at 'Big 5' hospitals like Samsung Medical Center and Severance Hospital, provides significant references for strengthening its market position.Expanding the supply of 'Unafra injection' to major general and university hospitals in Korea, particularly the successful passage of Pharmacy and Therapeutics Committee (DC) reviews at 'Big 5' hospitals like Samsung Medical Center and Severance Hospital, provides significant references for strengthening its market position.
- A robust pipeline of new drugs focused on pain and central nervous system diseases represents a core competitive strength, securing future growth engines and enabling continuous innovation for the company.A robust pipeline of new drugs focused on pain and central nervous system diseases represents a core competitive strength, securing future growth engines and enabling continuous innovation for the company.
- Pharmaceutical manufacturing and sales industryPharmaceutical manufacturing and sales industry
- Healthcare industryHealthcare industry
- Pain management and treatment sectorPain management and treatment sector
- Central Nervous System (CNS) disease treatment sector (Parkinson's, Alzheimer's, schizophrenia, etc.)Central Nervous System (CNS) disease treatment sector (Parkinson's, Alzheimer's, schizophrenia, etc.)
- Substance addiction treatment sector (opioid addiction, etc.)Substance addiction treatment sector (opioid addiction, etc.)
- South Africa (patent registration)South Africa (patent registration)
- South Korea, China (technology export discussions), Japan (patent registration, technology transfer target), Taiwan (patent registration), India (patent review in progress), Southeast Asia (export discussions)South Korea, China (technology export discussions), Japan (patent registration, technology transfer target), Taiwan (patent registration), India (patent review in progress), Southeast Asia (export discussions)
- European Union (EU) (patent review in progress, technology transfer target)European Union (EU) (patent review in progress, technology transfer target)
- United States (FDA approval pursuit, clinical trials, technology transfer target), Canada (patent review in progress)United States (FDA approval pursuit, clinical trials, technology transfer target), Canada (patent review in progress)
- Australia (patent review in progress)Australia (patent review in progress)
- Brazil (patent review in progress), Central/South America (export discussions)Brazil (patent review in progress), Central/South America (export discussions)
- Eurasian patent registration decision for the high-concentration injectable formulation of the non-narcotic analgesic 'Unafra injection'Eurasian patent registration decision for the high-concentration injectable formulation of the non-narcotic analgesic 'Unafra injection'
- Japanese substance patent registration approval for the oral non-narcotic analgesic candidate 'VVZ-2471' (also registered in the US, South Africa, China, and Taiwan)Japanese substance patent registration approval for the oral non-narcotic analgesic candidate 'VVZ-2471' (also registered in the US, South Africa, China, and Taiwan)
- Domestic patent registration for the 38th Korean new drug 'Unafra injection' (Opiranserin Hydrochloride) (expires November 29, 2032, with potential extension to 2037 upon extension application)Domestic patent registration for the 38th Korean new drug 'Unafra injection' (Opiranserin Hydrochloride) (expires November 29, 2032, with potential extension to 2037 upon extension application)
- Obtained US Food and Drug Administration (FDA) Investigational New Drug (IND) approval for the new drug candidate 'VVZ-2471'Obtained US Food and Drug Administration (FDA) Investigational New Drug (IND) approval for the new drug candidate 'VVZ-2471'
- US FDA Fast Track designation for the non-narcotic analgesic 'Unafra injection' (VVZ-149)US FDA Fast Track designation for the non-narcotic analgesic 'Unafra injection' (VVZ-149)
- Possession of manufacturing facilities certified with KGMP (Korean Good Manufacturing Practice), ensuring capabilities in pharmaceutical production and quality management.Possession of manufacturing facilities certified with KGMP (Korean Good Manufacturing Practice), ensuring capabilities in pharmaceutical production and quality management.